Current and Future Therapies for Hepatitis C Virus Infection

Overview

Journal N Engl J Med

Specialty General Medicine

Date 2013 May 17

PMID 23675659

Citations 183

Authors

T Jake Liang

Marc G Ghany

Affiliations

Soon will be listed here.

Citing Articles

Mapping the Hidden Terrain of Hepatocellular Carcinoma: Exploring Regional Differences in Incidence and Mortality across Two Decades by Using the Largest US Datasets.

Abboud Y, Shah V, Bebawy M, Al-Khazraji A, Hajifathalian K, Gaglio P J Clin Med. 2024; 13(17).

PMID: 39274469 PMC: 11396507. DOI: 10.3390/jcm13175256.

An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences.

Khalil R, Al-Mahzoum K, Barakat M, Sallam M Pathogens. 2024; 13(8).

PMID: 39204274 PMC: 11356961. DOI: 10.3390/pathogens13080674.

Evolutionary Invasion Analysis of Modern Epidemics Highlights the Context-Dependence of Virulence Evolution.

Surasinghe S, Kabengele K, Turner P, Ogbunugafor C Bull Math Biol. 2024; 86(8):88.

PMID: 38877355 PMC: 11178639. DOI: 10.1007/s11538-024-01313-0.

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections.

Izhari M Diagnostics (Basel). 2023; 13(19).

PMID: 37835845 PMC: 10572573. DOI: 10.3390/diagnostics13193102.

Evaluation of Plasma miR-17-5p, miR-24-3p and miRNA-223-3p Profile of Hepatitis C Virus-Infected Patients after Treatment with Direct-Acting Antivirals.

Oksuz Z, Gragnani L, Lorini S, Temel G, Serin M, Zignego A J Pers Med. 2023; 13(8).

PMID: 37623439 PMC: 10455277. DOI: 10.3390/jpm13081188.

References

Kiser J, Burton J, Anderson P, Everson G . Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012; 55(5):1620-8. PMC: 3345276. DOI: 10.1002/hep.25653. View

Liang T, Rehermann B, Seeff L, Hoofnagle J . Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000; 132(4):296-305. DOI: 10.7326/0003-4819-132-4-200002150-00008. View

Hopkins S, Bobardt M, Chatterji U, Garcia-Rivera J, Lim P, Gallay P . The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes. Antimicrob Agents Chemother. 2012; 56(7):3888-97. PMC: 3393457. DOI: 10.1128/AAC.00693-12. View

Li Y, Chang M, Abar O, Garcia V, Rowland C, Catanese J . Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol. 2009; 51(4):750-7. PMC: 2883297. DOI: 10.1016/j.jhep.2009.04.027. View

Backus L, Boothroyd D, Phillips B, Belperio P, Halloran J, Mole L . A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011; 9(6):509-516.e1. DOI: 10.1016/j.cgh.2011.03.004. View

Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie A, Reddy K, Bzowej N . Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405-16. DOI: 10.1056/NEJMoa1012912. View

Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon S . Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368(20):1878-87. DOI: 10.1056/NEJMoa1214853. View

Luscombe C, Huang Z, Murray M, Miller M, Wilkinson J, Ewart G . A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antiviral Res. 2010; 86(2):144-53. DOI: 10.1016/j.antiviral.2010.02.312. View

Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley R . Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis. 2012; 205(4):656-62. PMC: 3266130. DOI: 10.1093/infdis/jir802. View

10.

Einav S, Gerber D, Bryson P, Sklan E, Elazar M, Maerkl S . Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol. 2008; 26(9):1019-27. PMC: 4110250. DOI: 10.1038/nbt.1490. View

11.

Gane E, Roberts S, Stedman C, Angus P, Ritchie B, Elston R . Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010; 376(9751):1467-75. DOI: 10.1016/S0140-6736(10)61384-0. View

12.

Sarrazin C, Kieffer T, Bartels D, Hanzelka B, Muh U, Welker M . Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007; 132(5):1767-77. DOI: 10.1053/j.gastro.2007.02.037. View

13.

Werner C, Egetemeyr D, Lauer U, Nadalin S, Konigsrainer A, Malek N . Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl. 2012; 18(12):1464-70. DOI: 10.1002/lt.23542. View

14.

Liu S, Cipriano L, Holodniy M, Owens D, Goldhaber-Fiebert J . New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012; 156(4):279-90. PMC: 3586733. DOI: 10.7326/0003-4819-156-4-201202210-00005. View

15.

Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland J, Sodoyer M . Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol. 2002; 76(14):6919-28. PMC: 136313. DOI: 10.1128/jvi.76.14.6919-6928.2002. View

16.

Afdhal N, McHutchison J, Zeuzem S, Mangia A, Pawlotsky J, Murray J . Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology. 2011; 53(1):336-45. DOI: 10.1002/hep.24052. View

17.

Lawitz E, Godofsky E, Rouzier R, Marbury T, Nguyen T, Ke J . Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Res. 2011; 89(3):238-45. DOI: 10.1016/j.antiviral.2011.01.003. View

18.

Veldt B, Heathcote E, Wedemeyer H, Reichen J, Hofmann W, Zeuzem S . Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007; 147(10):677-84. DOI: 10.7326/0003-4819-147-10-200711200-00003. View

19.

Zeuzem S, Asselah T, Angus P, Zarski J, Larrey D, Mullhaupt B . Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology. 2011; 141(6):2047-55. DOI: 10.1053/j.gastro.2011.08.051. View

20.

Ly K, Xing J, Klevens R, Jiles R, Ward J, Holmberg S . The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012; 156(4):271-8. DOI: 10.7326/0003-4819-156-4-201202210-00004. View